Xolair denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Xolair as "Not FDA-Approved"

Xolair (omalizumab) holds FDA approval for several distinct indications — including moderate-to-severe allergic asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy (under a specific label update). A "not FDA-approved" denial from UHC almost always means one of three things: the prescription was written for an indication outside the approved label (off-label use), the ICD-10 diagnosis code on the claim did not map to an approved indication, or a billing or authorization error made the claim appear off-label.

## Why This Denial Is Typically Appealable

If your prescriber ordered Xolair for an on-label indication, the denial is likely a coding or administrative error — which is among the most correctable denial types. If the use is genuinely off-label, UHC's own medical policies may still authorize coverage when peer-reviewed evidence supports the use and standard alternatives have failed; check UHC's published coverage determination policy for Xolair directly.

## Federal Appeal Rights

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (job-based plans) or ACA §2719 (marketplace/individual plans). Submit within the deadline shown on your denial notice — typically 180 days.
• External review: After exhausting the internal appeal (or if UHC fails to decide in time), you may request an Independent Review Organization (IRO) review. The external review window is generally up to four months from the date of final internal denial. Expedited external review is available when your health is at serious risk.

## What to Gather

1. Diagnosis documentation — chart notes confirming the exact diagnosis and the ICD-10 code your provider used. 2. Prescribing label copy — download the current FDA-approved prescribing information for Xolair and identify which indication applies to you. 3. UHC coverage policy — obtain UHC's current medical policy for omalizumab and confirm which indication criteria they require. 4. Prescriber letter of medical necessity — your physician should explicitly state which FDA-approved (or evidence-supported off-label) indication applies, explain why Xolair is appropriate, and map the clinical facts in your chart to UHC's stated criteria.

## Criteria-Mapping Structure

Create a side-by-side table: in the left column, copy each criterion verbatim from the FDA label and from UHC's policy; in the right column, cite the exact date, test result, or clinical finding from your chart that satisfies it. This format makes reviewers' jobs easier and reduces the chance of a second denial on technical grounds.

## Next Step

Contact UHC's appeals department using the number on your Explanation of Benefits, reference the denial tracking number, and submit your internal appeal packet with the documentation above. Keep copies of everything and note the date and name of every person you speak with.